PL359727A1 - Crystalline pharmaceutical - Google Patents

Crystalline pharmaceutical

Info

Publication number
PL359727A1
PL359727A1 PL35972701A PL35972701A PL359727A1 PL 359727 A1 PL359727 A1 PL 359727A1 PL 35972701 A PL35972701 A PL 35972701A PL 35972701 A PL35972701 A PL 35972701A PL 359727 A1 PL359727 A1 PL 359727A1
Authority
PL
Poland
Prior art keywords
crystalline pharmaceutical
crystalline
pharmaceutical
lopinavir
disclosed
Prior art date
Application number
PL35972701A
Other languages
English (en)
Polish (pl)
Inventor
Daniel A. Dickman
Sanjay Chemburkar
James J. Fort
Rodger F. Henry
David Lechuga-Ballesteros
Yuping Niu
William Porter
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27065762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL359727(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/793,536 external-priority patent/US6608198B2/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of PL359727A1 publication Critical patent/PL359727A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL35972701A 2000-03-30 2001-03-21 Crystalline pharmaceutical PL359727A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53825700A 2000-03-30 2000-03-30
US09/793,536 US6608198B2 (en) 2000-03-30 2001-02-27 Crystalline pharmaceutical
PCT/US2001/009112 WO2001074787A2 (en) 2000-03-30 2001-03-21 Crystalline pharmaceutical

Publications (1)

Publication Number Publication Date
PL359727A1 true PL359727A1 (en) 2004-09-06

Family

ID=27065762

Family Applications (1)

Application Number Title Priority Date Filing Date
PL35972701A PL359727A1 (en) 2000-03-30 2001-03-21 Crystalline pharmaceutical

Country Status (22)

Country Link
EP (1) EP1268442A2 (bg)
JP (1) JP2003529592A (bg)
KR (1) KR100773258B1 (bg)
CN (2) CN1330639C (bg)
AR (2) AR033360A1 (bg)
AU (3) AU2001250920B2 (bg)
BG (1) BG107165A (bg)
BR (1) BR0109433A (bg)
CA (1) CA2403635A1 (bg)
CZ (1) CZ20023529A3 (bg)
HU (1) HUP0302675A3 (bg)
IL (1) IL151551A0 (bg)
MX (1) MXPA02009559A (bg)
MY (1) MY128296A (bg)
NO (1) NO325005B1 (bg)
NZ (1) NZ521183A (bg)
PE (1) PE20011232A1 (bg)
PL (1) PL359727A1 (bg)
SA (2) SA06270303B1 (bg)
SK (1) SK14832002A3 (bg)
TW (1) TWI284640B (bg)
WO (1) WO2001074787A2 (bg)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608198B2 (en) 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2010089753A2 (en) * 2009-02-06 2010-08-12 Hetero Research Foundation Novel polymorphs of lopinavir
WO2011025849A1 (en) * 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis c virus
CN112830899A (zh) * 2021-01-18 2021-05-25 合肥华方医药科技有限公司 一种洛匹那韦新晶型及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound

Also Published As

Publication number Publication date
JP2003529592A (ja) 2003-10-07
SA06270303B1 (ar) 2009-08-02
TWI284640B (en) 2007-08-01
HUP0302675A2 (hu) 2003-12-29
KR100773258B1 (ko) 2007-11-05
KR20030011807A (ko) 2003-02-11
WO2001074787A2 (en) 2001-10-11
NO20024679D0 (no) 2002-09-30
AU5092001A (en) 2001-10-15
NZ521183A (en) 2004-03-26
AU2001250920B2 (en) 2006-06-29
CN101066952A (zh) 2007-11-07
WO2001074787A3 (en) 2002-02-07
NO325005B1 (no) 2008-01-14
AU2006222711A1 (en) 2006-10-19
BR0109433A (pt) 2004-08-10
AR049560A2 (es) 2006-08-16
SK14832002A3 (sk) 2003-02-04
PE20011232A1 (es) 2001-12-08
MY128296A (en) 2007-01-31
AR033360A1 (es) 2003-12-17
CN1330639C (zh) 2007-08-08
HUP0302675A3 (en) 2004-03-29
CA2403635A1 (en) 2001-10-11
IL151551A0 (en) 2003-04-10
EP1268442A2 (en) 2003-01-02
MXPA02009559A (es) 2003-05-21
SA01220270B1 (ar) 2006-11-14
NO20024679L (no) 2002-09-30
CN1422259A (zh) 2003-06-04
BG107165A (bg) 2003-07-31
CZ20023529A3 (cs) 2003-02-12

Similar Documents

Publication Publication Date Title
AP1718A (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
EA199900373A2 (ru) Фармацевтические композиции
AU3652102A (en) Compounds and their uses
IS6254A (is) Lyfjasamsetningar sem innihalda HMG afoxunarensímlata
MY134136A (en) Novel compounds comprising jak3 kinase inhibitors
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
DK1221277T3 (da) Binaural synkronisering
MA26812A1 (fr) Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases
MXPA02009706A (es) Metodo para sintesis de perindopril y sus sales farmaceuticamente aceptables.
AU2001235691A1 (en) Use of paullone derivatives for making medicines
GB0006133D0 (en) Novel pharmaceutical
GB0017060D0 (en) Production, stabilisation and use of reduced forms of pharmaceutical compounds
MY133969A (en) Indoloquinazolinones
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
AU2002232468A1 (en) Pharmaceutical heterocyclic compounds
MXPA03000914A (es) Sintesis de (r)-3-(4 -bromobencil) -1-(3, 5-diclorofenil) -5-yodo-3 -metil-1-h -imidazo[1, 2-a]imidazol -2-ona.
PL359727A1 (en) Crystalline pharmaceutical
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
AP2002002547A0 (en) Calcilytic compounds.
FR2815332B1 (fr) Devidoir suspendu, notamment pour cultures
EP1383511A4 (en) CALCILYTIC COMPOUNDS
GB0021865D0 (en) Novel pharmaceutical
DE60212130D1 (en) Carvedilolpolymorph
GB0014006D0 (en) Novel pharmaceutical
AU2001264900A1 (en) Pharmaceutical use of fibulin-1

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)